stoxline Quote Chart Rank Option Currency Glossary
  
Aadi Bioscience, Inc. (AADI)
1.88  0.04 (2.17%)    05-28 16:00
Open: 1.87
High: 1.89
Volume: 88,532
  
Pre. Close: 1.84
Low: 1.82
Market Cap: 46(M)
Technical analysis
2024-05-28 4:50:34 PM
Short term     
Mid term     
Targets 6-month :  2.27 1-year :  2.48
Resists First :  1.95 Second :  2.13
Pivot price 1.88
Supports First :  1.65 Second :  1.38
MAs MA(5) :  1.86 MA(20) :  1.91
MA(100) :  1.92 MA(250) :  3.99
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  34.1 D(3) :  36.9
RSI RSI(14): 48.5
52-week High :  8.48 Low :  1.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AADI ] has closed above bottom band by 49.9%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.89 - 1.9 1.9 - 1.91
Low: 1.8 - 1.81 1.81 - 1.82
Close: 1.87 - 1.88 1.88 - 1.89
Company Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Headline News

Sun, 26 May 2024
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - br.ADVFN.com

Thu, 23 May 2024
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the ... - PR Newswire

Sat, 11 May 2024
Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Fri, 10 May 2024
Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts - Yahoo Finance

Fri, 10 May 2024
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI) - Simply Wall St

Wed, 01 May 2024
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 25 (M)
Shares Float 18 (M)
Held by Insiders 10.8 (%)
Held by Institutions 54.3 (%)
Shares Short 1,130 (K)
Shares Short P.Month 943 (K)
Stock Financials
EPS -2.45
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.34
Profit Margin -288.8 %
Operating Margin -364.6 %
Return on Assets (ttm) -33.2 %
Return on Equity (ttm) -58.3 %
Qtrly Rev. Growth -8.9 %
Gross Profit (p.s.) 0
Sales Per Share 0.97
EBITDA (p.s.) -3.04
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.78
PEG Ratio 0
Price to Book value 0.56
Price to Sales 1.93
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android